Last $0.79 USD
Change Today +0.02 / 2.60%
Volume 101.8K
OCLS On Other Exchanges
OCLS is not on other exchanges.
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $5.99
52 Week Low
01/30/15 - $0.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oculus innovative sciences i (OCLS) Related Businessweek News

No Related Businessweek News Found

oculus innovative sciences i (OCLS) Details

Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of organisms that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human advanced wound and tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company’s Microcyn has received eight 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

31 Employees
Last Reported Date: 01/20/15
Founded in 1999

oculus innovative sciences i (OCLS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $263.5K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $250.0K
Executive Vice President of International Ope...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences, Inc. Announces the Launch of a Intraderm Pharmaceuticals as a New Division

Oculus Innovative Sciences, Inc. announced the launch of a new division, IntraDerm Pharmaceuticals, which is intended to develop and commercialize advanced dermatological products for the professional dermatology markets in the United States and internationally. Headquartered in Petaluma, California, IntraDerm Pharmaceuticals is staffed with a seasoned management and sales team who are well versed in the dermatology prescription markets in both the United States and Europe.

Oculus Innovative Sciences, Inc. Approves Amendment to Restated Certificate of Incorporation

The Special Meeting of Stockholders of Oculus Innovative Sciences, Inc. was held on December 4, 2014. At the Special Meeting, the company's stockholders were asked to approve an amendment to the company's Restated Certificate of Incorporation, as amended, to increase the number of authorized common stock, $0.0001 par value per share, to a total number of 30,000,000 shares.

Oculus Innovative Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Oculus Innovative Sciences, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company reported total revenues of $3,264,000 against $4,089,000 a year ago. Loss from operations was $1,544,000 against $1,271,000 a year ago. Net loss was $718,000 against $1,399,000 a year ago. Basic and diluted net loss per share was $0.08 against $0.21 a year ago. Non-GAAP loss from operations minus non-cash expenses (EBITDAS) was $1,051,000 against $882,000 a year ago. The increased revenue was due to the strong growth in the sales of hydrogel and 120-milliliter liquid products. The decrease in net loss from the prior year is due to the mark-to-market adjustment of derivative liabilities related to outstanding common stock purchase warrants. For the six months, the company reported total revenues of $6,656,000 against $7,461,000 a year ago. Loss from operations was $3,058,000 against $2,397,000 a year ago. Net loss was $788,000 against $3,111,000 a year ago. Basic and diluted net loss per share was $0.09 against $0.47 a year ago. Non-GAAP loss from operations minus non-cash expenses (EBITDAS) was $2,050,000 against $1,595,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $0.79 USD +0.02

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,830 JPY +6.50
Henry Schein Inc $138.07 USD -1.94
Integra LifeSciences Holdings Corp $55.72 USD -1.90
Patterson Cos Inc $50.09 USD -0.89
Smith & Nephew PLC 1,191 GBp -9.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OCLS Industry Range
Price/Earnings 1.0x
Price/Sales 0.5x
Price/Book 0.5x
Price/Cash Flow 1.9x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at